The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.
Read More »Gut Microbiome – Identifying Children with Type 1 Diabetes
Artificial intelligence fingerprints gut flora, linking clusters of microbial species with type 1 diabetes development.
Read More »Preventing Diabetes with Antihypertensives
Researchers showed that elevated blood pressure is a modifiable risk factor for new-onset type 2 diabetes.
Read More »Black & Hispanic Americans Develop Diabetes Earlier in Life
The mean age at diagnosis of diabetes for non-Hispanic Black and Hispanic adults was 4-7 years earlier than for non-Hispanic white adults.
Read More »Processed Versus Intact Whole Grains and Glycemic Control
Many foods are marked with the whole-grain stamp of approval, but are these products equivalent in terms of glycemic control?
Read More »Preventing Misdiagnosis between Type 1 and Type 2
A program testing type 1 diabetes patients’ C-peptide levels found that approximately half of the group had a different form of diabetes.
Read More »Why Fractures and Falls in Type 2 Diabetes?
A prospective study found an increased risk for fractures and falls among older women with type 2 diabetes.
Read More »Efpeglenatide Has Cardiovascular and Renal Benefit Outcomes in Type 2 Diabetes
Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.
Read More »Linagliptin and Glimepiride
According to current research, linagliptin had a significantly lower risk of hypoglycemia and adverse events in geriatric patients with type 2 diabetes.
Read More »Risk of Herpes Zoster in Patients with Diabetes
A systematic review found patients with diabetes were associated with a 38% increased risk of developing herpes zoster.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.